Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Insertion of Green Fluorescent Protein into Nonstructural Protein 5A Allows Direct Visualization of Functional Hepatitis C Virus Replication Complexes
2004 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
2007 StandoutNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results
2013
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
2013
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Animal Models for the Study of Hepatitis C Virus Infection and Related Liver Disease
2012
Treatment triumphs
2014 StandoutNatureNobel
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
2013
DNA recognition by an RNA-guided bacterial Argonaute
2017 StandoutNobel
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures
2010 StandoutNobel
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells
2010 StandoutNobel
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir
2013
Whole Genome Pyrosequencing of Rare Hepatitis C Virus Genotypes Enhances Subtype Classification and Identification of Naturally Occurring Drug Resistance Variants
2012
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
2013
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
2013
Inherent Structural Disorder and Dimerisation of Murine Norovirus NS1-2 Protein
2012
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
2012
Metazoan MicroRNAs
2018 Standout
miRNA–target chimeras reveal miRNA 3′-end pairing as a major determinant of Argonaute target specificity
2015 StandoutNobel
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
2013 StandoutNobel
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
2010
Argonaute CLIP Defines a Deregulated miR-122-Bound Transcriptome that Correlates with Patient Survival in Human Liver Cancer
2017 StandoutNobel
Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids
2018 StandoutNobel
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Mouse liver repopulation with hepatocytes generated from human fibroblasts
2014 Nature
Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19
2012
Global control of hepatitis C: where challenge meets opportunity
2013
The Ligands of Estrogen Receptor α Regulate Cytochrome P4502C9 (CYP2C9) Expression
2011
Dancing with chemical formulae of antivirals: A panoramic view (Part 2)
2013
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Novel therapies for hepatitis C — one pill fits all?
2013
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
2013
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
Treatment of Chronic Hepatitis C: Current and Future
2013
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection
2004 StandoutNobel
Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice
2015 StandoutNobel
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains
2012
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
2013
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
2013
Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious Virus
2007 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry
2006 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect
2014
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
Structure-Function Analysis of Hepatitis C Virus Envelope-CD81 Binding
2000 StandoutNobel
Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents
2014 StandoutNobel
New therapeutic strategies in HCV: second‐generation protease inhibitors
2013
Enteric bacteria promote human and mouse norovirus infection of B cells
2014 StandoutScience
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
2014
Works of Anna Persson being referenced
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
2012
Regulation of CYP2C19 Expression by Estrogen Receptor α: Implications for Estrogen-Dependent Inhibition of Drug Metabolism
2010
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
2010